Comparative Bioinformatics Characteristic of Bladder Cancer Stage 2 from Stage 4 Expression Profile: A Network-Based Study

Mona Zamanian Azodi1, Mostafa Rezaei Tavirani2*, Mohammad Rostami-Nejad3, Majid Rezaei-Tavirani4

1 Student Research Committee, Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Bladder cancer (BC) has remained as one of the most challenging issues in medicine. The aim of this study was to investigate the differential network analysis of stages 2 and 4 of BC to better understand the molecular pathology of these states. Materials and Methods: We chose gene expression data of GSE52519 from Gene Expression Omnibus (GEO) database analyzed by the GEO2R online tool. Cytoscape version 3.6.1 and its algorithms are the methods applied for the network construction and investigation of differentially expressed genes (DEG) in these states. Result: Our result revealed that the analysis DEGs provides useful information about a common molecular feature of stages 2 and 4 of BC. Conclusion: Consequently, the network finding revealed that more investigation about stage 2 is required to achieve an effective therapeutic protocol to block the transition from stage 2 to stage 4. [GMJ.2018;7:e1279]
DOI:10.22086/gmj.v0i0.1279

Keywords: Bladder Neoplasm; Transcriptome; Protein Interaction Maps; Biomarkers

Introduction

Bladder cancer (BC), with the highest rate of death in underdeveloped countries, is the ninth most common type of cancer worldwide [1]. It is also accounted for the second most common type of urological cancer. The risk of BC is higher in men than women [2], with the report of at least 50% recurrence [3]. The available BC detection procedure, though useful, is costly and invasive [4]. In this view, the importance of applying a noninvasive and more sensitive method of detection has led to the application of different molecular investigations, including genomics, transcriptomics, and proteomics profiling. Using these approaches, we aimed to achieve an improved understanding of underlying disease mechanisms and providing a great impact in the clinic [5, 6]. There are several molecular investigations about BC that have reported the genes related to the disease. The role of ISG15, GIP2, Cyclin E P53, GSTM1, and several genes in BC is explored and approved [7-10].
Revealing disease-related mechanisms can be effective for developing therapeutic methods [11]. Furthermore, these molecular signatures could also be analyzed by protein interaction mapping via topological examinations. In the network concept, key proteins in a network constitution could be essential to the network integrity and function. For instance, in a disease condition, key proteins that are central to the strength of a network could be dysregulated [12]. As mentioned earlier, one way is to determine the gene expression profile by microarray to find the most key dysregulated genes in the network basis. The differentially expressed genes (DEG) data could be accessible from Gene Expression Omnibus (GEO) database for that specific state of interest, such as different types of cancers by using comparison and network analyzing methods. By doing this, it becomes feasible to provide more validity of identified biomarkers [13]. Following this, the enrichment analysis of the central proteins provides further information. Network analysis, therefore, could present multiple powerful therapeutic targets [14]. In this study, we aimed to examine DEG via protein interaction maps to find better biomarkers for stages 2 and 4 of BC, as bioinformatics can analyze and screen the genes related to various diseases to select the more important ones [15].

Materials and Methods

To analyze differential and common contributing biomarkers and pathways of BC in stages 2 and 4, the gene expression profiles were examined using bioinformatics. For this purpose, the keyword “Bladder cancer” was searched against the GEO database [16] (www.ncbi.nlm.nih.gov/geo/), and the appropriate study of the mRNA microarray dataset GSE52519 (Genome-wide analysis of gene expression in cancerous and normal human bladder tissues) was downloaded. Moreover, we applied the platform GPL6884, Illumina HumanWG-6 v3.0 expression beadchip, for this study. GEO2R Analyzer was the first bioinformatic study conductor here, which is a Web-based tool in GEO. GEO2R uses the GEO query and limma R packages from the Bioconductor project and provides different statistic information including P value, t test, and fold change for the detected DEGs among samples of interest [17]. The samples were organized into the following 3 groups: healthy (as control), stage 2 of BC, and stage 4 of BC. The dysregulated genes among the cancerous groups were prioritized based on their significant contribution to that specific stage and consequently considered for protein-protein interaction (PPI) network analysis. We used the Cytoscape version 3.6.1. application for the network data visualization and analysis. Network centrality is one of the fundamental concepts for the network [15]. After network data integration via the STRING database plug-in in Cytoscape, essential centrality parameters including degree and betweenness were explored by the use of Genetic Network Analyzer [18, 19]. Removal of central nodes can disrupt network communication, which may lead to the abnormal phenotype of a disease [20]. Furthermore, hub-bottlenecks were identified as genes with the highest values of degree and betweenness centrality [21]. To retrieve the functional data on DEGs and hub-bottlenecks in each experimental group of stages 2 and 4, we used GeneMANIA from http://www.genemania.org/plugin/ and Cytoscape platform. This application extracts interaction relations and functional annotation of the corresponding analyzed network [16].

Result

To elucidate the distribution of expression values of the 3 compared groups for cross-comparison, we used box plotting. Box plot analysis is available through the GEO2R Online Analyzer (see Figure-1). The finding indicates that the defined groups are comparable. Among 250 top genes in terms of differential expression in stages 2 and 4 of BC, 206 and 178 genes, respectively, showed significant differential changes (adjusted P value ≤.05 and FC ≥ 2). The Benjamini-Hochberg procedure (false discovery rate) was used as the default option (the data are not shown) for the adjustment test for P-value. Among these genes, the top 10 up-regulated and down-regulated
genes in stages 2 and 4 are listed in Figure-2. The related networks of BC stages 2 and 4 were constructed. In these networks, the physical interaction was used for centrality analysis. The obtained network of stage 2, including DEGs and 50 added neighbors, consists of 241 nodes and 1771 links. This query has both a linked component and individual ones. To analyze the network, we conducted subnetwork creation and extracted the first component consisting of 183 nodes and 1771 connections. Another network was made of significantly expressed genes in stage 4 of BC compared with control. This network comprised 278 nodes (DEGs plus 50 neighbors) and 4605 links. To analyze the whole interacting system, a subnetwork of 190 nodes and 4601 links were obtained as a connected component (the data are not shown). The parameters considered for network analysis are degree and betweenness centrality. The detailed interaction analysis for stages 2 and 4 are shown in Figures-3 and 4, respectively. As the mode of interaction can provide useful information, the network of top DEGs of both the stages was constructed based on pathway contribution, coexpression, colocalization, physical interaction, genetic interaction, and predicted functional relations via GeneMANIA (see Figures-5 and 6).

Discussion

Recent molecular studies have a major impact on disease clarification and are thus helpful for treatment approaches. Prioritizing gene sets related to a specific type of disease in terms of centrality features provides additional information for that disease state [22]. In this study, by studying significantly changed genes regarding their network properties, we prioritized them based on centrality role in the network strength. As indicated in Figure-1, samples are comparable [23] in terms of expression values, and so, the analysis can be done. The comparison shows that there are 6 common genes including PGM5, SYNM, CNN1, PI16, DES, and ACTC1 with differential expression values between stages 2 and 4. Surprisingly, all the common genes are down-regulated. Phosphoglucomutase is a metabolic enzyme that is involved in carbohydrate metabolism [24], and synemin is known as a cell adhesion and cell motility modulator [25]. Association of SYNM with early tumor relapse is investigated and reported [25]. The other 2 common genes Calponin (CNN1) and PI16 are related to the muscular cells [26, 27]. The role of desmin in skeletal and cardiac muscle and also ACTC1 in heart function are described in detail [28, 29]. It is observed that muscular function is the most common feature of the 2 studied stages. Centrality analysis of the significant DEGs in stages 2 and 4 followed by network construction in Figures-3 and 4 indicated that although none of the central genes in stage 2 are from the query ones, all of the critical genes of stage 4, except CDK1, are among DEGs. The presence or absence of query genes among the central nodes of the PPI network can be related to the information.
about their properties in the databases [30]. TOP2A, AURKB, BUB1, and BRIC5 are among the dysregulated genes. In addition, AURKB is up-regulated in both stages 2 and 4. It is not included in the selected top 10 changed expression genes, and it is not among the central genes of stage 2. It is reported that high levels of AURKB are associated with cytogenetic abnormality [31]. Further evaluations of central genes in stage 4 indicated that all the 4 hub-bottlenecks are up-regulated. These findings show that up-regulation is dominant among key genes of stage 4 and can be considered as a differential point between the stages. On the other hand, down-regulation is a common aspect between top DEGs of stag-

![Figure 2. Expression pattern of the top 10 down-regulated and up-regulated genes in stage 2 (A) and stage 4 (B) of BC. Vertical axis refers to fold change.](image-url)
Figure 3. The distribution of degree (right vertical axis) and betweenness centrality (left vertical axis) values of hub-bottlenecks at stage 2 of BC network are shown.

Figure 4. The distribution of degree (right vertical axis) and betweenness centrality (left vertical axis) values of hub-bottlenecks at stage 4 of BC network are shown.
es 2 and 4. Analyzing top DEGs of stages 2 and 4 as networks in Figures 5 and 6, respectively, indicates that coexpression is a dominant relationship between the genes. The 2 constructed networks are characterized by about 80% expression edges and a range of 1% to 4% physical interactions. This finding from the GeneMANIA network is in accordance with our finding from gene expression profiling of BC in different stages and further study by PPI network via the STRING database. As it was described in the Methods section, the PPI networks were constructed by additional 50 relevant genes. The poor interactions between the query genes required additional nodes to constitute the interactive units for stages 2 and 4 of BC. However, the pathway relationships between the 2 stages are inconsiderable in comparison with expression links; stage 2 is not as good as stage 4. Relative similarity between top DEGs and the central nodes is reported in other documents [32]. This finding refers to unmatched roles of the elements of stage 2 network relative to the nodes of stage 4 interactome. The main findings of this research can be summarized as follows:

1. The muscular system is the most involved tissue in stages 2 and 4 of BC.
2. There are large amounts of information about the involved elements of stage 4 relative to stage 2 of BC in the databases.
3. Up-regulation of the critical genes is the key feature of stage 4, whereas down-regulation of the top DEGs is the common process for the 2 studied stages.
4. Coexpression is the dominating relationship between DEGs in both the stages. Therefore, it is possible to introduce a differential method for the 2 stages, which may be useful in early-stage diagnosis of the disease. Although magnetic resonance imaging and pathology are used frequently to analyze the stage of different cancers [33], the molecular finding can improve the staging methods effectively and economically. On the basis of our finding, stages 2 and 4 of
BC can be differentiated, but more investigation, such as research in the field, is needed.

**Conclusion**

It can be concluded that based on DEG, there are significant common molecular maps and patterns between stages 2 and 4 of BC. PPI network analysis revealed the top DEGs as central genes in stage 4, but it showed the difference between DEGs and central genes of stage 2 BC. Therefore, more investigation about the molecular mechanism of stage 2 is required, which could be useful in the prevention of transition from stage 2 to 4 in BC.

**Acknowledgment**

This study is related to project NO. 1396/46461 from Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors also appreciate the “Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical Sciences for providing financial support to this study.

**Conflict of Interest**

There is no conflict of interest.

**References**

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017; 71(1):96-108.
2. Lezhnina K, Kovalchuk O, Zhavoronkov AA, et al. Novel robust biomarkers for human bladder cancer based on activation of intracellular signaling pathways. Oncotarget. 2014;5(19):9022-33.
3. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295(3):299-305.
4. D’Costa JJ, Goldsmith JC, Wilson JS, Bryan RT, Ward DG. A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer. Bladder Cancer. 2016;2(3):301-17.
5. Rezaei-Tavirani M, Rezaei-Tavirani S, Mansouri M, Rostami-Nejad M, Rezaei-Tavirani M. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. Asian Pac J Cancer Prev. 2017;18(12):3357-63.
6. Tyanova S, Albrechtsen R, Kronqvist P, Cox J, Mann M, Geiger T. Proteomic maps of breast cancer subtypes. Nat Commun. 2016;10259(7):1-11.
7. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst. 1993;85(14):1159-64.
8. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol. 2000;157(3):787-94.
9. Fujimoto K, Yamada Y, Okajima E, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res. 1992;52(6):1393-8.
10. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA, Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer. 2006;94(10):1465-71.
11. Khal J, Hine AV, Fearon KC, Dejong CH, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol. 2005;37(10):2196-206.
12. Mansouri V, Vafaee R, Abaszadeh H, Heidari M. Protein-protein interaction network anal-
ysis of obesity. Arvand J Health Medical Sci. 2016;1(3):157-62.
13. Valizadeh R, Bahadorimonfared A, Rezaei-Tavirani M, Norouzini M, Ehsani Arakani MI. Evaluation of involved proteins in colon adenocarcinoma: an interactome analysis. Gastroenterol Hepatol Bed Bench. 2017;10(Suppl1):S129-38.
14. Abdolahi H, AzodiMZ, Hatami B. Protein interaction mapping interpretation of non alcoholic fatty liver disease model of rats after fat diet feeding. Gastroenterol Hepatol Bed Bench. 2017;10(Suppl1):S146-53.
15. Tavirani MR, Okhovatian F, Rostami-Nejad M, Tavirani SR. Protein-protein interaction network analysis revealed a new prospective of posttraumatic stress disorder. GMJ. 2018;7:e1137
16. Montojo J, Zuberi K, Rodriguez H, et al. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics. 2010;26(22):2927-8.
17. Barrett T, Willhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991-5.
18. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.
19. Szklarczyk D, Morris JK, Cook H, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45(Database issue):D362-8.
20. Assenov Y, Ramirez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2007;24(2):282-4.
21. Peyvandi H, Peyvandi AA, Safaei A, Azodi MZ, Rezaei-Tavirani M. Introducing potential key proteins and pathways in human laryngeal cancer: a system biology approach. Iran J Pharm Res. 2018;17(1):415-25.
22. Rezaei-Tavirani M, Hasanzadeh H, Seyyedi S, Ghoujeghi F, Semnani V, Zali H. Proteomic analysis of Extremely Low-Frequency ElectroMagnetic Field (ELF-EMF) with different intensities in rats hippocampus. Arch Neurosci. 2018; 5(1):e62954.
23. Williamson DF, Parker RA, Kendrick JS. The box plot: a simple visual method to interpret data. Ann Intern Med. 1989;110(11):916-21.
24. Edwards YH, Putt W, Fox M, Ives JH. A novel human phosphoglucomutase (PGM5) maps to the centromeric region of chromosome 9. Genomics. 1995;30(2):350-3.
25. Noetzel E, Rose M, Sevence E, et al. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. Oncogene. 2010;29(34):4814.
26. Winder SJ, Walsh MP. Smooth muscle calponin. Inhibition of actomyosin MgATPase and regulation by phosphorylation. J Biol Chem. 1990;265(17):10148-55.
27. Hazell GG, Peachey AM, Teasdale JE, et al. PI16 is a shear stress and inflammation-regulated inhibitor of MMP2. Sci Rep. 2016; 6: 39553
28. Jiang HK, Qiu G, Li-Ling J, Xin N, Sun KL. Reduced ACTC1 expression might play a role in the onset of congenital heart disease by inducing cardiomyocyte apoptosis. Circ J. 2010;74(11):2410-8.
29. Milner DJ, Mavroidis M, Weisleder N, Capetanaki Y. Desmin cytoskeleton linked to muscle mitochondrial distribution and respiratory function. J Cell Biol. 2000;150(6):1283-98.
30. Rezaei–Tavirani M, Bashash D, Rostami FT, et al. Celiac disease microarray analysis based on system biology approach. Gastroenterol Hepatol Bed Bench. 2018;11(3):216-24.
31. Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res. 2011;35(2):260-4.
32. Zamanian-Azodi M, Rezaei-Tavirani M, Rostami-Nejad M, Tajik-Rostami F. New molecular aspects of cardiac arrest: promoting cardiopulmonary resuscitation approaches. Emerg. 2018;6(1):1-6.
33. Gandhi N, Krishna S, Booth CM, et al. Diagnostic accuracy of magnetic resonance imaging for tumour staging of bladder cancer: systematic review and meta-analysis. BJU Int. 2018.